Toronto, ON – September 8, 2025 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is happy to announce that it has completed import operations and release to the United States. PharmAla announced contracting of this new distribution site on March 24, 2025.
“With the full onboarding of our distribution facility, PharmAla is now in a position to service clinical trial clients in the US rapidly, and without the need for additional import operations,” said Nick Kadysh, Founding CEO, PharmAla Biotech. “Our numerous US clients and potential customers can rest assured that PharmAla will continue to work to make their critical research faster, cheaper, and easier – even in the face of global trade uncertainty and tariff risk.”
PharmAla’s agreement with its partner provides for a streamlined domestically-stored GMP-compliant supply of LaNeo™ MDMA for all clients already contracted. It provides certainty against regulatory and import/export risks for any clients seeking MDMA for clinical trials in the United States.
Resignation of Dr. Shane Morris
Dr. Shane Morris has resigned from his role as Chief Operating Officer of PharmAla Biotech, effective Friday, September 5. Dr. Morris’ role will be backfilled; Interested applicants may apply at the following link:
https://www.linkedin.com/jobs/view/4297157884/
PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.
Nicholas Kadysh, CEO
press@pharmala.ca